ClinicalTrials.gg
Sign In

Meningeal Carcinomatosis clinical trials

The registry lists 146 studies for Meningeal Carcinomatosis across more than 10 countries. 48 are recruiting or about to start. 78 of them are mainly about Meningeal Carcinomatosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Meningeal Carcinomatosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
45
Recruiting
33
Terminated
17
Status unknown
17
Not yet recruiting
13
Active, not recruiting
13

Phase

Phase 2
59
Phase 1
56
Phase 4
6
Phase 3
4
Early Phase 1
2

Where

United States
61
China
54
France
8
Netherlands
3
Taiwan
3
Switzerland
2

Who runs them

Guangzhou Medical University (8) · Duke University (5) · M.D. Anderson Cancer Center (5) · The First Hospital of Jilin University (5) · Memorial Sloan Kettering Cancer Center (5) · City of Hope Medical Center (4) · National Cancer Institute (NCI) (4) · NYU Langone Health (4)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 2 programmes from 2 companies, 2 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Stage, biomarker and line of therapy are not read yet: these programmes are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Jul 2027 est.Rhenium Re 186 Obisbemeda · Cerenome · Phase 2 main aimNCT07098806 Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases — primary endpoint: Maximum Tolerated Dose · 24 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Meningeal Carcinomatosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Pemetrexed6012
Aflutinib506
Rhenium Re 186 Obisbemeda203
Osimertinib104
Temozolomide104
Trastuzumab103
Nivolumab103
Trastuzumab deruxtecan102
AZD3759102
Thiotepa101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 8 open · Antimetabolites 7 open · Antibody-drug conjugates (ADCs) 3 open · Immune checkpoint inhibitors 2 open · Alkylating agents 2 open

Coming up

1phase 3 study under way
24studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 33 Meningeal Carcinomatosis studies recruiting now, 21 (64%) set no upper age limit and 10 (30%) stop at 75 or younger. 1 (3%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 33
AgeWomenMen
101 (3%)1 (3%)
1830 (91%)30 (91%)
3033 (100%)33 (100%)
4033 (100%)33 (100%)
5033 (100%)33 (100%)
6533 (100%)33 (100%)
7532 (97%)32 (97%)
8522 (67%)22 (67%)

Across all 146 studies, recruiting or not: 28% stop at 75 or younger and 5% at 65; 16% take children; 5% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 15, 2026.

Started recruiting2

Studies

Recruiting first, then most recently updated. Showing 50 of 146. Browse all 146 → or search them.